Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 4 from your keywords: subject="Lonide"
cover
Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis
Comment Share
Clave P

Otilonium bromide (OB) is a spasmolytic agent acting as an L-type calcium channel antagonist in intestinal and colonic smooth muscle cells (SMCs). We analyzed three independent clinical trials with homogeneous design on patients with irritable bowel syndrome (IBS). After 2 weeks receiving placebo, patients were randomized to receive OB (3 × 40 mg daily) or placebo for 15 weeks. We aimed to per…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Colonic smooth muscle cells and colonic motility patterns as a target for irr…
Comment Share
Rychter J

Otilonium bromide (OB) is a spasmolytic compound of the family of quaternary ammonium derivatives and has been successfully used in the treatment of patients with irritable bowel syndrome (IBS) due to its specific pharmacodynamic effects on motility patterns in the human colon and the contractility of colonic smooth muscle cells. This article examines how. OB inhibits the main patterns of human…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Long-term efficacy and safety of otilonium bromide in the management of irrit…
Comment Share
Triantafillidis JK

Irritable bowel syndrome (IBS) is a very common functional gastrointestinal disorder characterized by abdominal pain or discomfort and altered bowel habits. The disease affects a large part of the world population. The clinical course is mostly characterized by a cyclic recurrence of symptoms. Therefore, IBS patients should receive, as an initial therapeutic approach, a short course of treatmen…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Second Asian Consensus on Irritable Bowel Syndrome
Comment Share
Gwee KA

There has been major progress in our understanding of the irritable bowel syndrome (IBS), and novel treatment classes have emerged. The Rome IV guidelines were published in 2016 and together with the growing body of Asian data on IBS, we felt it is timely to update the Asian IBS Consensus

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-